NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Harrow, Inc. (HROW) Stock Analysis

Harrow, Inc. (HROW) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

HROW

$28.24

+$0.17 (+0.61%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HROW with… →

HROW Key Statistics

As of Oct 21, 2026
Trading
Open
$28.26
Previous Close
$28.07
Day's Range
27.98–28.66
52-Week Range
26.96–54.85
Volume
524.12K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.19
Valuation
Market Cap
$1.06B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
10.19
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.84
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.99
Financials (FY)
Revenue (FY)
$272.30M+36.41%
Net Income (FY)
−$5.14M
Profit marginThe share of revenue left as profit after all costs and taxes.
−13.51%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
37.49M
1-Year Return
−30.82%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
567.52K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, HROW closed at $28.24, −30.82% over 1 year.

Harrow, Inc. (HROW) has a market capitalization of $1.06B.

In fiscal 2025, HROW reported revenue of $272.30M.

HROW Stock Return by Calendar Year

Harrow, Inc. (HROW) 10-year return: what $10,000 became

1 year
$10,000 $6,918
−30.82%
5 years
$10,000 $29,024
+190.24%
10 years
$10,000 $94,448
+844.48%

If you had invested $10,000 in Harrow, Inc. (HROW) 10 years ago, at the close on October 21, 2016, it would have been worth $94,448 at the close on October 21, 2026: +844.48% in total, +25.18% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−42.37%
2025+46.05%
2024+199.55%
2023−24.12%
2022+70.83%
2021+25.95%
2020−11.83%
2019+36.73%
2018+234.71%
2017−32.00%
2016 (partial year)−36.55%

As of October 21, 2026.

HROW Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$272.30M−$5.14M−1.9%
2024$199.61M−$17.48M−8.8%
2023$130.19M−$24.41M−18.7%
2022$88.60M−$14.09M−15.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$272.30M$204.37M$30.52M−$5.14M−1.9%
2024$199.61M$150.37M$9.08M−$17.48M−8.8%
2023$130.19M$90.55M$811.00K−$24.41M−18.7%
2022$88.60M$63.21M$1.92M−$14.09M−15.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HROW Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricHROWDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio3.842.1083% above
Profit margin−13.51%−8.14%5.4 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Harrow, Inc. (HROW) is capitalised at $1.06B on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 373.

The most recent close on file for HROW is $28.24, dated October 21, 2026. That is +$0.17 (+0.61%) against the previous close. Over the past 52 weeks the price has ranged from $26.96 to $54.85. The latest close sits 4.75% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $272.30M. That is +36.41% against the prior fiscal year, when revenue was $199.61M. The same year closed with a net loss of $5.14M. Profit margin runs at −13.51%. That is 5.4 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are −0.99.

Across the 4 fiscal years on file, revenue moves from $88.60M in 2022 to $272.30M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 10.19. The price-to-sales ratio is 3.84. On price-to-sales that is 82.93% above the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

Over the trailing twelve months the total return is −30.82%. Measured over 10 years, that is +25.18% a year compounded. Beta against the wider market is reported at 0.19. Annualized volatility over the trailing 10 years is 71.19%.

Growth & Income

No dividend is on file for HROW.

2026 is still running; the total return is −42.37% year to date. The strongest complete calendar year on file is 2018 at +234.71%; the weakest is 2017 at −32.00%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Harrow, Inc. (HROW) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Harrow, Inc. HROW $1.06B —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Harrow, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Harrow, Inc.

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Visit website →